Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease:: Multicenter study of the gatekeeper reflux repair system

被引:53
作者
Fockens, P
Bruno, MJ
Gabbrielli, A
Odegaard, S
Hatlebakk, J
Allescher, HD
Rösch, T
Rhodes, M
Bastid, C
Rey, J
Boyer, J
Muehldorffer, S
van den Hombergh, U
Costamagna, G
机构
[1] Univ Amsterdam, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] Klinikum Rechts Der Isar, Munich, Germany
[4] Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England
[5] Wulfran Puget Hosp, Marseille, France
[6] Arnault Tzanck Inst, Nice, France
[7] CHU Angers, Angers, France
[8] Univ Erlangen Nurnberg, Erlangen, Germany
[9] SARL, Medtron Europe, Tolochenaz, Switzerland
[10] Catholic Univ, Rome, Italy
关键词
D O I
10.1055/s-2004-825665
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Study Aims: The safety and effectiveness of the Gatekeeper Reflux Repair System (Medtronic Europe, Tolochenaz, Switzerland) in the treatment of gastroesophageal reflux disease (GERD) was evaluated. This new, reversible treatment modality involves the endoscopic introduction of expandable polyacrylonitrile-based hydrogel prostheses into the esophageal submucosa to augment the lower esophageal sphincter (LES). Patients and Methods: For this study, data from two prospective, nonrandomized European multicenter trials were pooled. Sixty-nine GERD patients with heartburn and regurgitation and abnormal esophageal acid exposure (24-h pH <4.0 for >4% of the total time) who had responded to proton-pump inhibitor (PPI) therapy were recruited, and 68 were treated with up to six prostheses placed at the gastroesophageal junction. Patients underwent esophageal manometry, endoscopy, 24-h pH-metry, and symptom scoring at intake and 1, 3, and 6 months after the procedure. Results: A total of 77 procedures were performed in 67 patients, and a total of 270 prostheses were placed (mean 4.3 per procedure). At I and 6 months, 80.4% and 70.4% of the prostheses were retained, respectively. At 6 months, 24-h pH-metry outcomes with pH < 4.0 for > 4.0% of the time decreased from 9.1% to 6.1% (n = 45; P < 0.05). Median LES pressure increased significantly from 8.8 mmHg at baseline to 13.8 mmHg at 6 months (n = 42, P < 0.01). Median GERD heartburn-related quality-of-life scores improved significantly from 24.0 to 5.0 (n = 53, P < 0.01) in patients no longer receiving PPI therapy. Two serious adverse events (3.0%) occurred. Both patients recovered uneventfully. Prostheses were endoscopically removed from one patient without any adverse events. Conclusions: The Gatekeeper Reflux Repair System is a safe endoscopic treatment modality that significantly improves GERD symptoms and has objective effects on acid reflux.
引用
收藏
页码:682 / 689
页数:8
相关论文
共 26 条
[1]  
[Anonymous], GALL ORG NAT SURV HE
[2]   More pathophysiologically oriented treatment of GORD? [J].
Boeckxstaens, GE ;
Tytgat, GNJ .
LANCET, 2002, 359 (9314) :1267-1268
[3]   Complications and results of primary minimally invasive antireflux procedures: A review of 10,735 reported cases [J].
Carlson, MA ;
Frantzides, CT .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2001, 193 (04) :428-439
[4]   Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux:: a pilot study [J].
Devière, J ;
Pastorelli, A ;
Louis, H ;
de Maertelaer, V ;
Lehman, G ;
Cicala, M ;
Le Moine, O ;
Silverman, D ;
Costamagna, G .
GASTROINTESTINAL ENDOSCOPY, 2002, 55 (03) :335-341
[5]  
DiBaise JK, 2002, AM J GASTROENTEROL, V97, P833
[6]   Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis [J].
Edwards, SJ ;
Lind, T ;
Lundell, L .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (11) :1729-1736
[7]   The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life [J].
Farup, C ;
Kleinman, L ;
Sloan, S ;
Ganoczy, D ;
Chee, E ;
Lee, C ;
Revicki, D .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) :45-52
[8]  
Fass R, 2002, AM J GASTROENTEROL, V97, P1901
[9]  
Fennerty M Brian, 2003, Gastrointest Endosc Clin N Am, V13, P201, DOI 10.1016/S1052-5157(02)00116-2
[10]   The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment - Suggested disease management guidelines [J].
Fennerty, MB ;
Castell, D ;
Fendrick, AM ;
Halpern, M ;
Johnson, D ;
Kahrilas, PJ ;
Lieberman, D ;
Richter, JE ;
Sampliner, RE .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (05) :477-484